Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 outpatients meta-analysis

BLAZE-1 phase 3 (combo)
  NCT04427501		 RCTbamlanivimab/etesevimabplaceboCOVID 19 outpatientssome concern
518/517 suggested
  • suggested 71 % decrease in hospitalization or death (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 95 % decrease in deaths with a moderate degree of certainty due to some concern in risk of bias
OPTIMISE-C19 (bamlanivimab-etesevimab vs casirivimab-imdevimab)
  NCT04790786		 RCTbamlanivimab/etesevimabcasirivimab/imdevimab (Ronapreve)COVID 19 outpatientshigh
-/- inconclusive
    86% probability of equivalence between bamlanivimab-etesevimab and casirivimab-imdevimab at an odds ratio bound of 0.25
    BLAZE-1 phase 2 (combination with etesevimab)
          NCT04427501    		 RCTbamlanivimab/etesevimabplaceboCOVID 19 outpatientssome concern
    		112/156 inconclusive
      decreased SARS-CoV-2 log viral load at day 11 compared with placebo of –0.57 [95% CI, –1.00 to –0.14], P = .01
      BLAZE-4 unpublished
              NCT04634409      		 RCTbamlanivimab/etesevimabplaceboCOVID 19 outpatientsNA
      		158/153 safety concern
      • statistically significant 63 % decrease in viral clearance by day 7

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

       

      - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons